-
1.发明授权2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineaoplastic agents 有权2,4-二（异）芳基氨基（ - 氧基）-5-取代的嘧啶作为抗肿瘤剂公开(公告)号：US06838464B2
公开(公告)日：2005-01-04
申请号：US10203025
申请日：2001-02-26
IPC分类号： A61K31/505 , A61K31/506 , A61K31/5377 , A61P35/00 , A61P43/00 , C07D239/48 , C07D401/12 , C07D403/12 , C07D413/12 , C07D453/02 , C07D521/00 , C07D403/04
CPC分类号： C07D239/48 , C04B35/632 , C07D231/12 , C07D233/56 , C07D249/08 , C07D401/12 , C07D403/12
摘要： Pyrimidine derivatives of formula (I) wherein Q1, Q2, G and R1 are as defined within; and pharmaceutically acceptable salts and in vivo hydrolysable esters thereof are described. Processes for their manufacture, pharmaceutical compositions and their use as cyclin-dependent serine/threonine kinase (CDK) and focal adhesion kinase (FAK) inhibitors are also described.
摘要翻译： 其中Q 1，Q 2，G和R 1如在其中所定义的式（I）的嘧啶衍生物; 和其药学上可接受的盐和体内可水解的酯。 还描述了其制备方法，药物组合物及其作为细胞周期蛋白依赖性丝氨酸/苏氨酸激酶（CDK）和粘着斑激酶（FAK）抑制剂的用途。
-
2.发明授权2,4,DI (hetero-) arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents 有权2,4，DI（杂）芳基氨基（ - 氧基）-5-取代的嘧啶作为抗肿瘤剂公开(公告)号：US07067522B2
公开(公告)日：2006-06-27
申请号：US10995931
申请日：2004-11-24
IPC分类号： C07D239/48 , C07D403/04 , C07D401/12 , A61K31/506 , A61K35/00
CPC分类号： C07D239/48 , C04B35/632 , C07D231/12 , C07D233/56 , C07D249/08 , C07D401/12 , C07D403/12
摘要： Pyrimidine derivatives of formula (I) wherein Q1, Q2, G and R1 are as defined within; and pharmaceutically acceptable salts and in vivo hydrolysable esters thereof are described. Processes for their manufacture, pharmaceutical compositions and their use as cyclin-dependent serine/threonine kinase (CDK) and focal adhesion kinase (FAK) inhibitors are also described.
摘要翻译： 其中Q 1，Q 2，G和R 1的式（I）的嘧啶衍生物如本文所定义; 和其药学上可接受的盐和体内可水解的酯。 还描述了其制备方法，药物组合物及其作为细胞周期蛋白依赖性丝氨酸/苏氨酸激酶（CDK）和粘着斑激酶（FAK）抑制剂的用途。
-
3.发明授权2,4-di(hetero-)arylamino (oxy)-5-substituted pyrimidines as antineoplastic agents 失效2,4-二（异 - ）芳基氨基（氧基）-5-取代的嘧啶作为抗肿瘤剂公开(公告)号：US06649608B2
公开(公告)日：2003-11-18
申请号：US10203154
申请日：2002-08-06
申请人： Elizabeth Janet Pease , Gloria Anne Breault , Emma Jane Williams , Robert Hugh Bradbury , Jeffrey James Morris
发明人： Elizabeth Janet Pease , Gloria Anne Breault , Emma Jane Williams , Robert Hugh Bradbury , Jeffrey James Morris
IPC分类号： C07D23948
CPC分类号： C07D239/47 , C07D231/12 , C07D233/56 , C07D239/48 , C07D249/08 , C07D401/12 , C07D401/14 , C07D403/12 , C07D409/12 , C07D471/04
摘要： Pyrimidine derivatives of the formula (I), wherein: Q1 and Q2 are independently selected from aryl or carbon linked heteroaryl optionally substituted as defined within; and one or both Q1 and Q2 are substituted on a ring carbon by one substituent of the formula (Ia) or (Ia′), wherein: Y, Z, n, m Q3, G, R1, are as defined within; and pharmaceutically acceptable salts and in in vivo hydrolysable esters thereof are described. Processes for their manufacture, pharmaceutical compositions and their use as cyclin-dependent serine/threonine kinase (CDK) and focal adhesion kinase (FAK) inhibitors are also described.
摘要翻译： 式（I）的嘧啶衍生物，其中：Q 1和Q 2独立地选自如上定义的任选取代的芳基或碳连接的杂芳基; 并且Q1和Q2中的一个或两个在环碳上由式（Ia）或（Ia'）的一个取代基取代，其中：Y，Z，n，m Q3，G，R 1如 ; 和其药学上可接受的盐及其体内可水解的酯。 还描述了其制备方法，药物组合物及其作为细胞周期蛋白依赖性丝氨酸/苏氨酸激酶（CDK）和粘着斑激酶（FAK）抑制剂的用途。
-
公开(公告)号：US06710052B2
公开(公告)日：2004-03-23
申请号：US10203549
申请日：2002-08-08
IPC分类号： C07D23948
CPC分类号： C07D239/47 , C07D417/12
摘要： Pyrimidine derivatives of the formula (I) wherein: one of Q1 and Q2 or both of Q1 and Q2 is substituted on a ring carbon by one substituent of the formula (Ia) [provided that when present in Q1 the substituent of formula (Ia) is not adjacent to the —NH— link]; wherein Q1, Q2, G, R1, X, Y1, Y2, Z, n and m are as described within; and pharmaceutically acceptable salts and in vivo hydrolyzable esters thereof are described. Processes for their manufacture, pharmaceutical compositions and their use as cyclin-dependent serine/threonine kinase (CDK) and focal adhesion kinase (FAK) inhibitors are also described.
摘要翻译： 式（I）的嘧啶衍生物其中：Q1和Q2中的一个或Q1和Q2两者在环碳上被式（Ia）的一个取代基取代[条件是当在Q1中存在式（Ia）的取代基时， 不与-NH-链接相邻]; 其中Q 1，Q 2，G，R 1，X，Y 1，Y 2，Z，n和m如上所述; 和其药学上可接受的盐和体内可水解的酯。 还描述了其制备方法，药物组合物及其作为细胞周期蛋白依赖性丝氨酸/苏氨酸激酶（CDK）和粘着斑激酶（FAK）抑制剂的用途。
-
公开(公告)号：US20120329795A1
公开(公告)日：2012-12-27
申请号：US13607999
申请日：2012-09-10
IPC分类号： A61K31/517 , A61P35/00 , A61K31/5377
CPC分类号： C04B35/632 , C07D401/12
摘要： The invention concerns quinazoline derivatives of Formula I: wherein each of R1, X1, R2, R3, R5, n and m have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours which are sensitive to inhibition of EGF and erbB receptor tyrosine kinases.
摘要翻译： 本发明涉及式I的喹唑啉衍生物：其中R1，X1，R2，R3，R5，n和m各自具有本说明书中定义的任何含义; 其制备方法，含有它们的药物组合物及其在制备用于预防或治疗对EGF和erbB受体酪氨酸激酶的抑制敏感的肿瘤中作为抗增殖剂的药物中的用途。
-
公开(公告)号：US20100292222A1
公开(公告)日：2010-11-18
申请号：US12776970
申请日：2010-05-10
IPC分类号： A61K31/551 , C07D487/04 , A61K31/5025 , C07D243/08 , A61P35/00
CPC分类号： C07D487/04
摘要： The invention concerns bicyclic compounds of Formula (I) wherein, R1, R2, R3, R4, R5, X1, X2, Y, k, m, n and p are as defined in the description. The present invention also relates to processes for the preparation of such compounds, pharmaceutical compositions containing them and their use in the treatment of androgen-receptor associated conditions, particularly prostate cancer.
摘要翻译： 本发明涉及式（I）的双环化合物，其中R1，R2，R3，R4，R5，X1，X2，Y，k，m，n和p如说明书中所定义。 本发明还涉及制备这些化合物的方法，含有它们的药物组合物及其在治疗雄激素受体相关病症，特别是前列腺癌中的用途。
-
公开(公告)号：US20100267699A1
公开(公告)日：2010-10-21
申请号：US12702603
申请日：2010-02-09
申请人： Robert Hugh Bradbury , Gregory Richard Carr , Alfred Arthur Rabow , Srinivasa Rao Korupoju , Harikrishna Tumma
发明人： Robert Hugh Bradbury , Gregory Richard Carr , Alfred Arthur Rabow , Srinivasa Rao Korupoju , Harikrishna Tumma
IPC分类号： A61K31/551 , C07D487/04 , A61K31/5025 , C07D243/08 , A61P35/00
CPC分类号： A61K31/5025 , A61K31/551 , A61K31/58 , C07D471/04 , C07D487/04
摘要： The invention concerns bicyclic compounds of Formula I wherein , R1, R2, L1, L2, J, Y, k, n, p and r are as defined in the description. The present invention also relates to processes for the preparation of such compounds, pharmaceutical compositions containing them and their use in the treatment of androgen-receptor associated conditions, particularly prostate cancer.
摘要翻译： 本发明涉及式I的双环化合物，其中R1，R2，L1，L2，J，Y，k，n，p和r如说明书中所定义。 本发明还涉及制备这些化合物的方法，含有它们的药物组合物及其在治疗雄激素受体相关病症，特别是前列腺癌中的用途。
-
公开(公告)号：US20080096881A1
公开(公告)日：2008-04-24
申请号：US10571991
申请日：2004-09-15
IPC分类号： A61K31/517 , A61K31/496 , A61K31/5377 , A61P35/00 , C07D401/12 , C07D401/14 , C07D413/14
CPC分类号： C04B35/632 , C07D401/12
摘要： The invention concerns quinazoline derivatives of Formula (I): wherein each of R1, X1, R2, R3, R5, n and m have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours which are sensitive to inhibition of EGF and erbB receptor tyrosine kinases.
摘要翻译： 本发明涉及式（I）的喹唑啉衍生物：其中R 1，X 1，R 2，R 3， R 5，n和m具有本说明书中定义的任何含义; 其制备方法，含有它们的药物组合物及其在制备用于预防或治疗对EGF和erbB受体酪氨酸激酶的抑制敏感的肿瘤中作为抗增殖剂的药物中的用途。
-
公开(公告)号：US20100029696A1
公开(公告)日：2010-02-04
申请号：US11817391
申请日：2006-02-28
申请人： Robert Hugh Bradbury
发明人： Robert Hugh Bradbury
IPC分类号： A61K31/517 , C07D401/14 , A61P35/00
CPC分类号： C07D401/14 , C07D417/14
摘要： A quinazoline derivative of the Formula (I) wherein the substituents are as defined in the text for use in the production of an anti proliferative effect which effect is produced alone or in part by inhibiting erbB2 receptor tyrosine kinase in a warm blooded animal such as man.
摘要翻译： 式（I）的喹唑啉衍生物，其中取代基如用于产生抗增殖作用的文本中所定义，其作用单独或部分通过在温血动物例如人中抑制erbB2受体酪氨酸激酶产生 。
-
10.发明申请公开(公告)号：US20090029968A1
公开(公告)日：2009-01-29
申请号：US12095659
申请日：2006-11-29
IPC分类号： A61K31/517 , C07D455/02 , A61P35/00 , A61K31/55
CPC分类号： C07D239/94
摘要： A quinazoline derivative of the Formula I: wherein the substituents are as defined in the text for use in the production of an anti-proliferative effect which effect is produced alone or in part by inhibiting erbB2 receptor tyrosine kinase in a warm-blooded animal such as man.
摘要翻译： 式I的喹唑啉衍生物：其中取代基如用于产生抗增殖作用的文本中所定义，其作用单独或部分通过在温血动物中抑制erbB2受体酪氨酸激酶产生，例如 人。
-
-
-
-
-
-
-
-
-
搜索结果
31 条记录 (耗时 0.03 秒)
